Drug Profile
GS 6201
Alternative Names: CVT-6883Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Developer Gilead Sciences
- Class Antiasthmatics; Purines; Pyrazoles; Small molecules
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung disorders